DiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q2 2019 Results - Earnings Call Transcript [Seeking Alpha]
DiaMedica Therapeutics Inc. (DMAC)
Last diamedica therapeutics inc. earnings: 11/13 04:12 pm
Check Earnings Report
Company Research
Source: Seeking Alpha
DiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q2 2019 Results - Earnings Call Transcript DiaMedica Therapeutics Inc. (NASDAQ: DMAC Company Participants Rick Pauls - President & CEO Scott Kellen - CFO Harry Alcorn - Chief Medical Officer Conference Call Participants Alex Nowak - Craig-Hallum Capital Thomas Flaten - Lake Street Capital Kyle Bauser - Dougherty & Company Operator Good morning, ladies and gentlemen, and welcome to the DiaMedica Therapeutics Second Quarter 2019 Conference Call. An audio recording of the webcast will be available shortly after the call today on DiaMedica's website at www.diamedica.com in the Investor section. Before the company proceeds with its remarks, please note that the Company will be making forward-looking statement on today's call. These statements are subject to risk and uncertainties that could cause results to differ materially from those projected in these statements. More information including the factors that could cause our actual resul
Show less
Read more
Impact Snapshot
Event Time:
DMAC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DMAC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DMAC alerts
High impacting DiaMedica Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
DMAC
News
- DiaMedica Therapeutics Inc. (NASDAQ: DMAC) is now covered by analysts at Craig Hallum. They set a "buy" rating and a $8.00 price target on the stock.MarketBeat
- DiaMedica (DMAC) Up as Stroke Study Dosing Begins Post Relaunch [Yahoo! Finance]Yahoo! Finance
- DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke [Yahoo! Finance]Yahoo! Finance
- DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic StrokeBusiness Wire
- DiaMedica Therapeutics (DMAC) Loses -19.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner [Yahoo! Finance]Yahoo! Finance
DMAC
Earnings
- 11/13/23 - Beat
DMAC
Sec Filings
- 4/10/24 - Form 8-K
- 4/10/24 - Form EFFECT
- 4/4/24 - Form ARS
- DMAC's page on the SEC website